Esther Rajavelu, Chief Executive Officer and Chief Financial Officer of Spero Therapeutics, Inc. (NASDAQ:SPRO), filed a Form 4 on November 10, 2026, disclosing a sale of 40,851 shares of common stock on November 9, 2026, to cover tax withholding obligations arising from the vesting of restricted stock units.

Key Highlights

  • Reporting person: Esther Rajavelu, serving as both Chief Executive Officer and Chief Financial Officer of Spero Therapeutics, Inc.
  • Shares sold: 40,851 shares of common stock disposed of on November 9, 2026, with transaction code S.
  • Sale price: $1.04 per share, according to the filing.
  • Purpose of sale: The filing states the shares were "required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs" via a "sell to cover" transaction.
  • Not discretionary: The filing notes the "sale occurred automatically to satisfy the tax withholding obligations" and "does not represent a discretionary trade by the Reporting Person."
  • Remaining holdings: Following the transaction, Rajavelu directly beneficially owns 946,000 shares of common stock.

Spero Therapeutics CEO and CFO Reports Automatic RSU Tax-Withholding Sale

According to the Form 4 filed with the SEC on November 10, 2026, Esther Rajavelu, who holds the dual role of Chief Executive Officer and Chief Financial Officer at Spero Therapeutics, Inc. (NASDAQ:SPRO), disposed of 40,851 shares of common stock on November 9, 2026, at a price of $1.04 per share. The transaction is coded "S" in Table I of the filing, indicating a sale of non-derivative securities.

The filing's explanation of responses clarifies that this transaction was not initiated at the reporting person's discretion. The shares sold "represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs," and the sale "occurred automatically to satisfy the tax withholding obligations to be funded by a 'sell to cover' transaction." No derivative security transactions were reported in Table II.

Following the reported transaction, Rajavelu directly beneficially owns 946,000 shares of Spero Therapeutics common stock. The form was signed by Maegan Deare as Attorney-in-Fact for Esther Rajavelu and filed on November 10, 2026. The date of the earliest transaction listed is November 6, 2026, as stated on the form's cover.

What Was Disclosed

Spero Therapeutics CEO and CFO Esther Rajavelu reported the automatic sale of 40,851 common shares at $1.04 per share on November 9, 2026, to satisfy tax obligations connected to RSU vesting, leaving her with direct beneficial ownership of 946,000 shares.